BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240827
DTEND;VALUE=DATE:20240830
DTSTAMP:20260515T163241
CREATED:20240515T095016Z
LAST-MODIFIED:20240515T095016Z
UID:39106-1724716800-1724975999@www.pharmajournalist.com
SUMMARY:3rd Digital Biomarkers & Clinical Measures for Neurology Summit
DESCRIPTION:Delivering on the Promise of Precision Medicine with Digital Measures in Neurology \nHarnessing More Quantitative\, Objective & Less Invasive Measures to Reduce Costs & Improve Neurology Patient Experience \n2023 welcomed SV95C as the first ever digital endpoint qualified by a regulatory agency\, which means that the floodgates have now opened to the potential of digital biomarkers to transform clinical development in neurology. \nFrom the latest validated research on implementing speech\, cognition\, and motor tracking measures into clinical development\, to navigating the regulatory and commercial landscape\, the 3rd Digital Biomarkers & Clinical Measures for Neurology Summit is the ultimate platform to take your digital strategy to the next level. \nThis August\, join 80+ senior industry leaders across digital health\, medical affairs\, clinical development\, and regulatory this year from Biogen\, DEEP Measures\, Janssen\, Alexion Pharmaceuticals\, Eisai\, Pfizer\, Novo Nordisk\, Novartis\, Boehringer Ingelheim\, Takeda\, MTP\, BMS\, Alto Neurosciences\, Michael J. Fox Foundation\, Cerevel Therapeutics\, Regeneron and many more…
URL:http://www.pharmajournalist.com/event/3rd-digital-biomarkers-clinical-measures-for-neurology-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240827
DTEND;VALUE=DATE:20240830
DTSTAMP:20260515T163241
CREATED:20240730T144029Z
LAST-MODIFIED:20240730T144412Z
UID:39475-1724716800-1724975999@www.pharmajournalist.com
SUMMARY:3rd Oligonucleotide CMC & Analytical Development Summit
DESCRIPTION:Exclusively dedicated to uniting AD\, QC\, and CMC leaders the 3rd Oligonucleotide CMC & Analytical Development Summit is the only industry-led meeting solving your impurity\, regulatory\, and cost-efficiency challenges in this rapidly evolving field. \nAcross the three days\, you’ll get the chance to hear from KOLs like Ionis Pharmaceuticals\, AstraZeneca\, and CAMP4 Therapeutics as the present their data-driven case studies on managing quality\, regulatory affairs\, and cost-efficient manufacturing. \nDeep dive into the major challenges of streamlining analytical tools\, process development\, and look towards greener chemistries to ensure global uptake of oligonucleotide drugs. \nThis isn’t just an event\, it’s an investment in the future of your teams’ technical capabilities. Bringing together siRNA\, mRNA\, ASO\, oligo and oligo-conjugate developers\, this definitive summit fosters comprehensive development\, ensuring the resilience and longevity of this rapidly advancing modality. \nJoin us this August to assess the field\, take back actionable insights to your team\, and realize the potential of oligonucleotide therapeutics for prevalent diseases and improved market acceptance. \nEvent highlights: \n\n3 interactive workshops across CMC consideration\, oligo-conjugate analytical and detection methods\, and how to establish a robust control strategy\n18 data-driven case studies from complex oligo synthesis to scale-up and quality control. This is your end-to-end guide for oligo commercialization\n100+ industry experts across Analytical Development\, CMC and QC teams in attendance\, allowing you to connect\, benchmark and strive towards common goals together\n\nExpert speakers include: \n\nAngela Tsai\, Senior Manager – Collaboration & External Innovation\, Sanofi\nGeorge Bou-Assaf\, Associate Director\, Biogen\nHuijun Tian\, Director\, Analytical Development & Quality Control\, QurAlis\nIsaiah Cedillo\, Assistant Director – Manufacturing & Operations\, Ionis Pharmaceuticals\nJanine Tom\, Senior Principal Scientist\, Amgen\nSatya Kuchimanchi\, Senior Vice President\, Technical Operations\, Chemistry\, Manufacturing & Controls\, CAMP4 Therapeutics\n\n100+ Industry Experts | 3 Interactive Workshops | 20% Off Group Discounts | Data-Driven Case Studies \nTo know more visit: https://ter.li/eptndw
URL:http://www.pharmajournalist.com/event/3rd-oligonucleotide-cmc-analytical-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR